Health Care Roundup: Market Talk

The newest Market Talks masking the Health Care sector. Published solely on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0830 GMT – Merck KGaA’s failed late-stage scientific research for its evobrutinib experimental drug in a number of sclerosis suggests related drug candidates must clear a excessive bar, Jefferies analysts say in a analysis be aware. The outcomes of the German pharmaceutical-and-chemical group’s scientific trials appear as a result of a greater efficiency than anticipated from Sanofi’s Aubagio, the drug in opposition to which evobrutinib’s efficacy in lowering the relapse charge of a number of sclerosis was being examined, Jefferies says. “This suggests to us that the bar for success in MS studies isn’t what we thought it was, and could pose risk to ongoing studies for [Sanofi’s] tolebrutinib, [Roche Holding’s] fenebrutinib and [Novartis’s] remibrutinib,” Jefferies says. (adria.calatayud@dowjones.com)